TY  - JOUR
AU  - Ghorashian, Sara
AU  - Jacoby, Elad
AU  - De-Moerloose, Barbara
AU  - Rives, Susana
AU  - Bonney, Denise
AU  - Shenton, Geoff
AU  - Bader, Peter
AU  - Bodmer, Nicole
AU  - Molinos-Quintana, Agueda 
AU  - Herrero, Blanca
AU  - Algeri, Mattia
AU  - Locatelli, Franco
AU  - Vettenranta, Kim
AU  - Gonzalez, Berta
AU  - Attarbaschi, Andishe
AU  - Harris, Stephen
AU  - Bourquin, Jean Pierre
AU  - Baruchel, Andre
PY  - 2022
DO  - 10.1016/S2352-3026(22)00225-3
UR  - http://hdl.handle.net/10668/22560
T2  - The Lancet. Haematology
AB  - Children aged younger than 3 years were excluded from the ELIANA phase 2 trial of tisagenlecleucel in children with acute lymphoblastic leukaemia. The feasibility, safety, and activity of tisagenlecleucel have not been defined in this group, the...
LA  - en
PB  - The Lancet Publishing Group
KW  - Tisagenlecleucel
KW  - Infant Acute Lymphoblastic Leukemia
KW  - KMT2A-Rearranged Leukemia
KW  - CAR T-Cell Therapy
KW  - Overall Survival
KW  - Event-Free Survival
KW  - B-Cell Aplasia
KW  - Cytokine Release Syndrome
KW  - Neurotoxicity
KW  - Child, Preschool
KW  - Humans
KW  - Infant
KW  - Precursor Cell Lymphoblastic Leukemia-Lymphoma
KW  - Receptors, Antigen, T-Cell
KW  - Receptors, Chimeric Antigen
KW  - Retrospective Studies
TI  - Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study.
TY  - research article
VL  - 9
ER  -